RFPL4AL1: A Potential Drug Target and Biomarker (G729974)

Target Name: RFPL4AL1

NCBI ID: G729974

RFPL4AL1

RFPL4AL1: A Potential Drug Target and Biomarker

The regulation of finger development and growth is a critical process in development, and any defects in this process can lead to various diseases, including polydactylia, a condition characterized by the overgrowth of the digits. One of the key proteins involved in this process is the Ret finger protein like 4A like 1 (RFPL4AL1), which has been identified as a potential drug target and biomarker.

The RFPL4AL1 Protein

RFPL4AL1 is a 21-kDa protein that is expressed in a variety of tissues, including fetal tissues, adult tissues, and cancer cells. It is a member of the superfamily of finger proteins, which are involved in the development and maintenance of the digits. The protein is composed of 118 amino acid residues and has a calculated pI of 9.99.

Function and Interaction

RFPL4AL1 is involved in the regulation of digit development and is highly expressed in tissues that are involved in this process, such as the embryonic digit primordium and the developing digits. It has been shown to play a role in the development and maintenance of the distal portion of the finger, including the bones and muscles that support the hand.

In addition to its role in finger development, RFPL4AL1 is also involved in the regulation of cell growth and has been shown to play a role in the development and progression of various cancers. This suggests that it may be a valuable drug target for the treatment of cancers that involve finger or hand injuries.

Drug Intervention Strategies

The potential drug intervention strategies for RFPL4AL1 are currently being investigated in various in vitro and in vivo models. One approach is to use RNA interference (RNAi) to knock down the expression of RFPL4AL1 and to assess the impact on the development and progression of cancer cells. This approach has been shown to be effective in a variety of cancer types, including lung cancer, breast cancer, and colon cancer.

Another approach is to use small molecules to inhibit the activity of RFPL4AL1 and to assess the impact on the development and progression of cancer cells. This approach has been shown to be effective in a variety of cancer types, including lung cancer, breast cancer, and colon cancer.

Biomarker Potential

The expression of RFPL4AL1 has been shown to be associated with the development and progression of various cancers, including lung cancer, breast cancer, and colon cancer. This suggests that it may be a valuable biomarker for the detection and diagnosis of these cancers. In addition, the expression of RFPL4AL1 has also been shown to be associated with the development and progression of polydactylia, a condition characterized by the overgrowth of the digits.

Conclusion

RFPL4AL1 is a protein that is involved in the regulation of finger development and growth, as well as the development and progression of various cancers. Its potential as a drug target and biomarker makes it an attractive target for further investigation and may lead to the development of new treatments for these diseases.

Protein Name: Ret Finger Protein Like 4A Like 1

The "RFPL4AL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RFPL4AL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets